CC 11050

Drug Profile

CC 11050

Alternative Names: CC-11050

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation
  • Phase Unknown Tuberculosis
  • Discontinued Cutaneous lupus erythematosus

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in Inflammation (Treatment-experienced) in USA (PO) (NCT02652546)
  • 26 Mar 2013 Celgene completes a phase II trial in Cutaneous lupus erythematosus in USA (NCT01300208)
  • 04 Feb 2005 Phase-I clinical trials in Cutaneous lupus erythematosus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top